What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines?

Nanomedicine

Volumn 10, Issue 3, 2015, Pages 343-345

  Kumar, Abhinav ^a   Forbes, Ben ^a   Mudway, Ian ^b   Bicer, Elif Melis ^b   Dailey, Lea Ann ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Faculty of Medicine and MRC Health Protection Agency   (United Kingdom)

Author keywords

alveolar macrophages; complement; inhaled nanomedicines; protein corona; pulmonary drug delivery; respiratory tract lining fluid; surfactant proteins

Indexed keywords

LIPID; NANOPARTICLE; RESPIRATORY TRACT AGENT; SILICA NANOPARTICLE; LUNG SURFACTANT;

BIOCOMPATIBILITY; CULTURE MEDIUM; EDITORIAL; HUMAN; INHALATIONAL DRUG ADMINISTRATION; IONIC STRENGTH; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; NANOMEDICINE; PLASMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PROTEIN INTERACTION; RESPIRATORY SYSTEM; RESPIRATORY TRACT LINING FLUID; SURFACE CHARGE; SURFACE PROPERTY; DRUG DELIVERY SYSTEM; METABOLISM; PROCEDURES;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; PULMONARY SURFACTANTS; RESPIRATORY SYSTEM;

EID: 84923632587     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.2     Document Type: Editorial

References (20)

1. Nguyen EV, Gharib SA, Schnapp LM., et al. Shotgun MS proteomic analysis of bronchoalveolar lavage fluid in normal subjects. Proteomics Clin. Appl. 8, 737-747 (2014
2. Kingma PS, Whitsett JA. In defense of the lung: surfactant protein A and surfactant protein D. Curr. Opin. Pharmacol. 6, 277-283 (2006
3. Serrano AG, Pérez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem. Phys. Lipids 141, 105-118 (2006
4. Kumar A, Bicer M, Pfeffer P., et al. Inhaled nanoparticles develop a complex protein corona: biological importance and implications for sustained release formulations. Presented at: Drug Delivery to the Lungs - DDL25. Edinburgh, UK, 10-12 December 2014
5. Monopoli MP, Walczyck D, Campbell A., et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133, 2525-2534 (2011
6. Tenzer S, Docter D, Kuharev J., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotech. 8, 772-781 (2013
7. Ruge CA, Schaefer UF, Herrmann J., et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS ONE 7(7), e40775 (2012
8. Schleh C, Rothen-Rutishauser B, Kreyling WG. The influence of pulmonary surfactant on nanoparticulate drug delivery systems. Eur. J. Pharm. Biopharm. 77, 350-352 (2011
9. Dailey LA, Jekel N, Fink L., et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol. 215(1), 100-108 (2006
10. Nassimi M, Schleh C, Lauenstein H., et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 75, 107-116 (2010
11. Harush-Frenkel O, Bivas-Benita M, Nassar T., et al. A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Toxicol. Appl. Pharmacol. 246(1-2), 83-90 (2010
12. Jones M-C, Jones SA, Riffo-Vasquez Y., et al. Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility. J. Control. Release 183(1), 94-104 (2014
13. Dailey LA. Considerations for the design of toxicity studies of inhaled nanomedicines. In: Nanotoxicology: From In Vivo and In Vitro Models to Health Risks. Sahu SC, Casciano DA (Eds). Wiley, Chichester, England (2009
14. Beck-Broichsitter M, Ruppert C, Schmehl T., et al. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomed. Nanotechnol. Biol. Med. 7, 341-350 (2011
15. Banquy X, Suarez F, Argaw A., et al. Effect of mechanical properties of hydrogel nanoparticles on macrophage cell uptake. Soft Matter 5, 3984-3991 (2009
16. Son Y-J, McConville JT. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int. J. Pharm. 382, 15-22 (2009
17. Salvati A, Pitek AS, Monopoli MP., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8, 137-143 (2013
18. Kendall M, Ding P, Mackay RM., et al. Surfactant protein D (SP-D) alters cellular uptake of particles and nanoparticles. Nanotoxicology 7, 963-973 (2013
19. Oosting RS, Wright JR. Characterization of the surfactant protein A receptor: cell and ligand specificity. Am. J. Physiol. 267, L165-L172 (1994
20. Caracciolo G, Cardarelli F, Pozzi D., et al. Selective targeting capability acquired with a protein corona adsorbed on the surface of 1,2-dioleoyl-3-Trimethylammonium propane/.DNA nanoparticles. ACS Appl. Mater. Interfaces 5, 13171-13179 (2013